DAKT Q1 2026 Earnings EPS Misses Estimates Stock Rises Despite Disappointing Start RDZN Q1 2026 Earnings Deep EPS Miss and Revenue Disclosure Gap GSK Q1 2026 Earnings Strong EPS Beat Drives Modest Stock Uptick FCRX Q1 2026 Earnings Narrow Miss on EPS Stable Note Performance SPB Q1 2026 Earnings EPS Surpasses Estimates by 127 Stock Declines 14 ONBPO Edges Higher Old National Bancorp Preferred Shares Approach Resistance ChipMOS Technologies IMOS Gains Momentum A Strong Session Above Key Support CAMP4 Therapeutics Surges 45 as Biotech Sentiment Improves CAMP Tests Key Resistance PACS Group Hovers Near Support in LowVolatility Trading PRLD Q1 2026 Earnings Narrower Loss Than Anticipated as Clinical Pipeline Advances